CD47 Antigen Inhibitors Market: How New Treatments Are Set to Change The market by 2034| DelveInsight

According to DelveInsight's analysis, the growth of the CD47 Antigen Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline activity for cancer indications in the 7MM.

DelveInsight's CD47 Antigen Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CD47 Antigen Inhibitors, market share of individual therapies, and current and forecasted CD47 Antigen Inhibitors market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the CD47 Antigen Inhibitors Market Report

• As per DelveInsight's analysis, The anti-CD47 drugs market was estimated to be worth $0.1 billion in 2023. It is expected to grow at a compound annual growth rate (CAGR) of over 42.9%
• Gilead Sciences has recently halted development of its CD47-targeting drug magrolimab in blood cancers, specifically in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The decision followed a Phase 3 study that showed an increased risk of death from infections and respiratory failure. The FDA placed a full clinical hold on the studies, affecting both expanded access programs
• ALX Oncology's evorpacept (ALX148) is making strides. It is being evaluated in multiple trials, including combinations with Cetuximab and Pembrolizumab for colorectal cancer, Venetoclax and Azacitidine for AML, and Rituximab for B-cell non-Hodgkin lymphoma. These trials are still ongoing and aim to assess safety and efficacy in these combinations
• Another key player is ImmuneOnco, whose CD47 inhibitor IMM-01 has entered Phase 3 trials in China, in combination with PD-1 inhibitor tislelizumab. This trial is seen as pivotal for the development of CD47 inhibitors in solid tumors
• Some of the key CD47 Antigen Inhibitors in the include: Evorpacept (ALX148) PT217, Herceptin, Cyramza, Paclitaxel, Pembrolizumab, Magrolimab, IMM-0, TTI-621 and TTI-622, CC-90002, AO-176, 5F9
• Leading CD47 Antigen Inhibitors companies such as ALX Oncology, Gilead Sciences, ImmuneOnco, Trillium Therapeutics, Celgene, Arch Oncology, Forty Seven, Inc.

Discover which therapies are expected to grab the CD47 Antigen Inhibitors market share @ https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

CD47 Antigen Inhibitors Market Overview
CD47 is a transmembrane protein in CD47 Therapeutics Market that acts as a high affinity signaling receptor for the secreted protein thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPA, SIRPα) and SIRPγ (SIRPG). CD47 inhibitors work by targeting the CD47 protein, which is commonly found on the surface of cancer cells. CD47 acts as a "don't eat me" signal, preventing the immune system's macrophages from engulfing and destroying these cancerous cells.

CD47 Antigen Inhibitors Epidemiology
CD47 antigen is overexpressed in various cancers, particularly in hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and non-Hodgkin lymphomas (NHL), as well as in solid tumors like colorectal cancer, ovarian cancer, and gastric cancer. The prevalence of cancers where CD47 is targeted varies, but AML, for example, has an incidence of around 20,000 new cases annually in the U.S., with MDS and NHL adding significantly to the overall patient population that could benefit from CD47-targeted therapies

To know more about CD47 Antigen Inhibitors clinical trials, visit @ https://www.delveinsight.com/sample-request/cd47-antigen-inhibitors-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
CD47 Antigen Inhibitors Dynamics

CD47 Antigen Inhibitors Market Drivers

• Unmet Medical Need in Cancer: Traditional therapies like chemotherapy and radiation often cause systemic toxicities and high relapse rates.
• Rise in Cancer Prevalence: The increasing incidence of cancers, particularly in aging populations, is a significant driver for the CD47 inhibitor market.
• Promising Clinical Results: Early clinical data for CD47 inhibitors, especially combination therapies (e.g., with immune checkpoint inhibitors), show potential efficacy in improving treatment outcomes.
• Advancements in Immunotherapy: The broader adoption and success of immunotherapies, including checkpoint inhibitors and CAR-T therapies, have paved the way for CD47 inhibitors.

CD47 Antigen Inhibitors Market Barriers

• Clinical Setbacks: Despite early promise, some trials have encountered safety concerns. For example, Gilead Sciences halted the development of magrolimab for AML and MDS due to safety risks like increased infections.
• Complexity of Immune Interactions: CD47 inhibitors rely on intricate immune system mechanisms, which may not work equally well across all cancers or patient populations.
• Competition and Innovation: The field of immuno-oncology is highly competitive, with numerous companies working on various approaches to target cancer.
• Cost of Development: The costs of running long-term clinical trials and meeting regulatory requirements can be substantial.

CD47 Antigen Inhibitors Treatment Market
CD47-targeted therapies, including antibody-based therapies, CAR T-cell therapy, and combination therapies, have shown promise in enhancing anti-tumor immunity and improving clinical outcomes.

CD47-targeted immunotherapies aim to enhance anti-tumor immunity and improve clinical outcomes by disrupting the "don't eat me" signal between CD47 (on cancer cells) and SIRPα (on myeloid cells). One of the approach is to use blocking antibodies or small molecules that inhibit this interaction, leading to increased phagocytosis of cancer cells by macrophages and promoting an anti-tumor immune response

Learn more about the FDA-approved CD47 Antigen Inhibitors @ https://www.delveinsight.com/sample-request/cd47-antigen-inhibitors-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Emerging CD47 Antigen Inhibitors and Companies
• Evorpacept (ALX148) PT217, Herceptin, Cyramza, Paclitaxel, Pembrolizumab: ALX Oncology
• Magrolimab: Gilead Sciences
• IMM-01: ImmuneOnco
• TTI-621 and TTI-622: Trillium Therapeutics
• CC-90002: Celgene
• AO-176: Arch Oncology
• 5F9: Forty Seven, Inc.

Scope of the CD47 Antigen Inhibitors Market Report

• Study Period: 2020-2034
• Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key CD47 Antigen Inhibitors Companies: ALX Oncology, Gilead Sciences, ImmuneOnco, Trillium Therapeutics, Celgene, Arch Oncology, Forty Seven, Inc.
• Key CD47 Antigen Inhibitors Therapies: Evorpacept (ALX148) PT217, Herceptin, Cyramza, Paclitaxel, Pembrolizumab, Magrolimab, IMM-0, TTI-621 and TTI-622, CC-90002, AO-176, 5F9
• CD47 Antigen Inhibitors Therapeutic Assessment: Current marketed and emerging therapies
• CD47 Antigen Inhibitors Market Dynamics: CTLA-4 Market drivers and CTLA-4 barriers
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, CD47 Antigen Inhibitor Market Access and Reimbursement

Discover more about CD47 Antigen Inhibitors drugs in development @ https://www.delveinsight.com/sample-request/cd47-antigen-inhibitors-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Reasons to buy CD47 Antigen Inhibitors report
• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the CD47 inhibitors Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of CD47 Inhibitors
4. Key Events
5. Market Forecast Methodology
6. CD47 Inhibitors Market Overview at a Glance in the 7MM
7. CD47 Inhibitors: Background and Overview
8. Target Patient Pool
9. Emerging Therapies
10. CD47 Inhibitor: Seven Major Market Analysis
11. Market Access and Reimbursement
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Appendix
16. Bibliography
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Ram Kapoor
info@delveinsight.com
+14699457679
www.delveinsight.com

This release was published on openPR.